Kiora Pharmaceuticals has filed a notice of an exempt offering of securities to raise $15,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Kiora Pharmaceuticals is raising up to $15,000,000.00 in new funding. Sources indicate that as part of senior management Director, Laurent Assaraf played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc. (Kiora) is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision. Kiora’s pipeline is comprised of multiple New Chemical Entities for the restoration of vision in patients with orphan retinal diseases. Stay tuned as we advance these assets with key clinical milestones in the upcoming 12 to 18 months.
To learn more about Kiora Pharmaceuticals, visit http://kiorapharma.com/
Contact:
Laurent Assaraf, Director
619-629-3073
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.